Tenaya Therapeutics (TNYA) Cash from Financing Activities (2020 - 2026)

Tenaya Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$415000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 100.83% year-over-year to -$415000.0; the TTM figure through Mar 2026 stood at $57.7 million (up 12.67% YoY), while the FY2025 annual figure was $108.4 million, up 127.03% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$415000.0, down from $58.2 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $77.5 million in Q4 2022, with the low at -$501000.0 in Q1 2023.
• The 5-year median for Cash from Financing Activities is $374000.0 (2023), against an average of $14.8 million.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities soared 369080.95% in 2022, then slumped 3440.0% in 2023.
• Tenaya Therapeutics' Cash from Financing Activities stood at $77.5 million in 2022, then plunged by 99.52% to $371000.0 in 2023, then rose by 1.62% to $377000.0 in 2024, then soared by 15348.81% to $58.2 million in 2025, then slumped by 100.71% to -$415000.0 in 2026.
• Business Quant data shows TNYA's Cash from Financing Activities at -$415000.0 in Q1 2026, $58.2 million in Q4 2025, and $380000.0 in Q3 2025.